DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Celgene (NASDAQ: CELG)

114.44 -0.49 (-0.43%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CELG $114.44 -0.43%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $114.87
Previous Close $114.93
Daily Range $114.00 - $116.00
52-Week Range $75.62 - $129.06
Market Cap $90.8B
P/E Ratio 39.36
Dividend (Yield) $0.00 (0.0%)
Volume 4,346,976
Average Daily Volume 4,872,050
Current FY EPS $4.11

Sector

Healthcare

Industry

Drug Makers

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website: http://www.celgene.com/

News & Commentary

Biotech Investment Opportunities for the Long Term

Biotech stocks have a history of outperforming the broad-market indexes -- if you pick the right ones. Here are three biotech investment opportunities for the long term that you should be considering.

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Amgen has shelved its once-promising psoriasis drug. Should investors worry?

Investing for Beginners: How to Start in Biotech

Biotech can be tricky to learn, so we asked the experts to give their best advice to beginners. Here is what they said.

The Highest Paid CEOs in Biotech

These highest paid CEOs in biotech brought in a minimum of $24 million in compensation in 2014. Find out what makes these leaders so special, and whether or not their exorbitant pay packages are sustainable.

BMO: Celgene Still A Buy On This 'Important Future Driver'

Undervalued Stocks in Biotech Worth Buying

Even though the term "bubble" is being tossed around with regard to biotech stocks, there are still three undervalued stocks in the sector worth buying.

As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect Fr

As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect From Biotech Next

Celladon's Failure Shouldn't Trickle Down To Other Gene Therapy Biotechs

Big Pharma Companies Are Betting On Regenerative Medicine - Should You?

Pop! 3 To Buy If Biotech Stocks Burst

Biotech stocks are falling slightly from their lofty levels, and that may create some interesting opportunities to buy.

See More CELG News...

CELG's Top Competitors

CELG $114.44 (-0.43%)
Current stock: CELG
AMGN $156.26 (-0.69%)
Current stock: AMGN
GILD $112.27 (-0.51%)
Current stock: GILD
$0.00 (0.00%)
Current stock: